This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Evrim Resources Corp. (TSX-V:EVM) (“Evrim” or the “Company”) is pleased to announce that further to its news release of February 20, 2018, the Company has signed a Definitive Agreement (the “Agreement”) with a subsidiary of Coeur Mining, Inc. (“Coeur”) in respect of the Sarape epithermal gold-silver project in Sonora, Mexico. Coeur will have the exclusive right to acquire up to an 80% interest in Sarape by spending up to US$16.
CDE FR EVM CDEUW AG
TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- Kerr Mines Inc. (TSX:KER) (OTC:KERMF) (FRA:7AZ1) (“Kerr” or the “Company”) is pleased to announce the appointment of Mr. David Thomas as Vice President of Projects and Copperstone Mine General Manager. This key addition to the Kerr Mines executive management team is central to the Company’s core strategy of moving into production in 2019.
CDE KERMF AISCF KGC K CDEUW TCKRF KER TECK
In this part of the series, we’ll analyze the correlation of the mining stocks to gold. Gold is the most dominant of the four precious metals, and silver, platinum, and palladium are known to closely track the movement in gold. Also, precious metals, though they belong to the equity segment of the market, are more dependent on where precious metals move, especially gold.
CDE ABX CDEUW ABX
With continuing downward sentiment in precious metals, it’s important to look at what large traders and hedge funds are doing with their positions in metals. This article focuses on silver, which is predominantly a precious metal and acts as a buffer along with gold during market unrest. Silver was trading at $16.4 per ounce as of 9:00 AM. The resistance level for silver is at a 50-day moving average of $16.
CDE FR PAAS HL CDEUW AG HL.PRB
All four precious metals witnessed a choppy market on May 15. Gold dropped about 2.1% and closed at $1,288.90 per ounce. This is the lowest level of gold so far this year, and these low levels were last seen in December 2017 for an ~$29.00 decline. The RSI level for gold was 29, which indicates a possible reversion in price.
CDE ELD CDEUW EGO
In 2017 and 2018 year-to-date, silver miners considerably underperformed silver. Miners are usually a leveraged play on metals, rising by a higher proportion when metal prices rise and falling harder when metal prices weaken. This trend hasn’t been visible lately as company-specific factors exerted more influence on stock prices.
CDE FR PPPMF PAAS HL CDEUW AG PPP P HL.PRB
In this final part of the series, we’ll look at the correlation between gold and four mining stocks: Randgold Resources (GOLD), Yamana Gold (AUY), Coeur Mining (CDE), and Barrick Gold (ABX). Mining stocks generally move with gold prices. Among these four miners, Yamana Gold has shown the highest correlation with gold this year, while Randgold has the lowest correlation on a year-to-date basis.
CDE ABX AUY YRI RGORF CDEUW GOLD RRS GOLD ABX
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to CDE / Coeur Mining, Inc. on message board site Silicon Investor.
as of ET